The LAT CAB is a new cross-disease long-acting technologies (LAT) community advisory board focused on malaria, the hepatitis C virus, and latent TB infection.
Materials in this section
LAT CAB reviews the state of treatment research, contributes to research protocols, and engages in the research and development process for long-acting technologies for malaria, HCV, and LTBI. More
A patent landscape, released by TAG, investigates potential patent barriers for the development and delivery of long-acting formulations for selected hepatitis C and TB medicines. More
October 2021 issue of TAGline delves deep into the development of long-acting formulations for the treatment and prevention of HIV, TB, hepatitis C, and malaria. More
Medicines Patent Pool Secures its First Licence on Promising Long-Acting Technologies for Malaria, TB, and Hepatitis C
The licence covers the patents and expertise of promising long-acting injectable technologies that could be applied in three disease areas with a high prevalence in LMICs. More
The Glossary compiles frequent terms and concepts used in the research and development of long-acting technologies. More